• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Premarket Approval (PMA)

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | Registration & Listing | Adverse Events | Recalls | PMA | Classification | Standards | Inspections
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 


New Search Back to Search Results
Note: this medical device record is a supplement. The device description may have changed. Be sure to look at the original PMA to get an up-to-date view of this device.
 
Trade NamePHOSPHORYLCHOLINE (PC) COATED BIODIVYSIOH SV STENT PREMOUNTED ON AN OVER-THE-WIRE (OTW) DELIVERY SYST SV OTW), AND PC C)
Classification Namestent, coronary
Generic Nameintravascular coronary stent
ApplicantBIOCOMPATIBLES CARDIOVASCULAR, INC.
PMA NumberP000011
Supplement NumberS003
Date Received06/28/2001
Decision Date12/21/2001
Product Code
MAF[ Registered Establishments with MAF ]
Advisory Committee Cardiovascular
Supplement Typenormal 180 day track
Expedited Review Granted? No
Combination Product No
Approval Order Statement 
Approval for: 1) the biodivysio(tm) sv otw in 10 mm, 15 mm and 18 mm stent lengths and 2. 0 mm and 2. 5 mm diameters. The device, as modified, will be marketed under the trade name biodivysio(tm) sv otw and is indicated for "improving coronary luminal diameter in subjects experiencing abrupt closure or threatened abrupt vessel closure following percutaneous revascularization of de novo or non in-stent restenotic native coronary artery lesions (length of lesion and/or dissection <=25 mm) with a reference vessel diameter ranging from >=2. 0 mm to <=3. 0 mm by visual estimate. Long-term outcome (beyond 6 months) for this implant is unknown at present. " 2) the biodivysio(tm) as otw in 11 mm and 15 mm stent lengths and 3. 0 mm, 3. 5 mm and 4. 0 mm diameters. The device, as modified, will be marketed under the trade name biodivysio(tm) as otw and is indicated for improving coronary luminal diameter in the following: a)subjects with symptomatic ischemic heart disease due to de novo native coronary artery lesions (length <=25 mm) with a reference vessel diameter ranging from >=3. 0 mm to 4. 0 mm; b)subjects experiencing aburpt closure or threatened abrupt vessel closure following percutaneous revascularization of de novo or non in-stent restenotic native coronary artery lesions (length of lesion and/or dissection <=25 mm) with reference vessel diameter ranging from >=3. 0 mm to <=4. 0 mm by visual estimation. Long term outcome (beyond 6 months) for these permanent implants are unknown at present.
-
-